Cardiac Structure and Function in People with Cystic Fibrosis.

Autor:	Duus LS; Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev & Gentofte. Hospital, Gentofte Hospitalsvej 8, 2900 Hellerup, University of Copenhagen, Denmark., Dons M; Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev & Gentofte. Hospital, Gentofte Hospitalsvej 8, 2900 Hellerup, University of Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Blegdamsvej 3B, 2200 Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: maria.flarup.dons.01@regionh.dk., Thudium RF; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Nielsen SD; Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Blegdamsvej 3B, 2200 Copenhagen, University of Copenhagen, Denmark; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Olsen MF; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark; Department of Nutrition, Exercise and Sports, Faculty of Science, Nørre Allé 51, 2200 Copenhagen, University of Copenhagen, Denmark., Qvist T; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Lassen MCH; Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev & Gentofte. Hospital, Gentofte Hospitalsvej 8, 2900 Hellerup, University of Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Blegdamsvej 3B, 2200 Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Skaarup KG; Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev & Gentofte. Hospital, Gentofte Hospitalsvej 8, 2900 Hellerup, University of Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Blegdamsvej 3B, 2200 Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Johansen ND; Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev & Gentofte. Hospital, Gentofte Hospitalsvej 8, 2900 Hellerup, University of Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Blegdamsvej 3B, 2200 Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Bluhme TM; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Katzenstein TL; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Pressler T; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Faurholt-Jepsen D; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Blegdamsvej 3B, 2200 Copenhagen, University of Copenhagen, Denmark; Cystic Fibrosis Centre, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark., Biering-Sørensen T; Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Copenhagen University Hospital - Herlev & Gentofte. Hospital, Gentofte Hospitalsvej 8, 2900 Hellerup, University of Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Blegdamsvej 3B, 2200 Copenhagen, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, 2730 Herlev, Denmark; Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2024 Sep 28. Date of Electronic Publication: 2024 Sep 28.
DOI:	10.1016/j.jcf.2024.09.012
Abstrakt:	Background: The extent of cardiac involvement in cystic fibrosis (CF) remains to be determined. The remarkable therapeutic advancements with new highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment and subsequent increase in life expectancy substantiates further research. We aimed to explore the prevalence of cardiac alterations in people with CF (pwCF) compared to matched controls and investigate potential cardiovascular risk factors. Methods: In this cross-sectional study, 104 pwCF underwent clinical and echocardiographic assessment. All participants were matched 1:1 with controls from the general population. Results: Of 104 pwCF, 44 % were female, mean age was 34 years, and 93 % received CFTR modulator treatment. The prevalence of abnormal cardiac function in pwCF was 44 %, more than double the prevalence in controls. PwCF were found to have smaller left ventricular (LV) dimensions, worse LV diastolic function, and reduced right ventricle (RV) as well as LV systolic function. After multivariable adjustment, LV diastolic function as well as LV and RV systolic function remained poorer in pwCF as compared to controls. Male sex and decreasing FEV1/FVC ratio remained independently associated with abnormal cardiac function in pwCF (male sex: OR 3.94 (1.56; 9.95), p = 0.004 and FEV1/FVC ratio: OR 2.05 per 0.1 unit decrease (1.21; 3.52), p = 0.008, respectively). Conclusions: Both left- and right-sided cardiac alterations were found in pwCF. After adjustments for risk factors, both RV and LV systolic measures remained altered in pwCF, compared to controls. Male sex and decreasing pulmonary function evaluated by FEV1/FVC-ratio were associated with abnormal cardiac function in pwCF. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RFT reports: Travel grant from Gilead. SDN reports: Advisory Board: Gilead, Takeda and GSK; Speaker honorarium: Gilead, Merck and GSK; Research grant: Novo Nordisk Foundation. KGS reports: Advisory Board: Sanofi Pasteur. TBS reports: Advisory Board: Sanofi Pasteur, Amgen, CSL Seqirus and GSK; Speaker honorarium: Bayer, Novartis, Sanofi Pasteur, GE healthcare and GSK; Research grants: Boston Scientific, GE Healthcare, AstraZeneca, Novo Nordisk and Sanofi Pasteur; Consultant appointments: Novo Nordisk, IQVIA and Parexel. (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect